Open AccessIn-Silico Identification of the Best Compound Against <i>Leishmania infantum</i>: High Throughput Screening of All FDA Approved Drugs
Author(s) -
Jasem Saki,
Farnoush Shadnoush,
Reza Arjmand,
Fakher Rahim
Publication year - 2019
Publication title -
türkiye parazitoloji dergisi/türkiye parazitoloji dergisi
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.207
H-Index - 18
eISSN - 2146-3077
pISSN - 1300-6320
DOI - 10.4274/tpd.galenos.2019.6290
Subject(s) - leishmania infantum , in silico , computational biology , identification (biology) , leishmania , biology , pharmacology , medicine , leishmaniasis , genetics , computer science , gene , visceral leishmaniasis , world wide web , parasite hosting , botany
Current in-silico research was designed and administered for the screening of 20000 Food and Drug Administration-approved drug compounds with the goal of finding promising drugs against lipophosphoglycan (LPG) and γ-glutamylcysteine synthetase (γ-GCS) of Leishmania infantum .